No evidence of data manipulation in the scientific publication on simufilam

News and research before you hear about it on CNBC and others. Claim your one week free trial for StreetInsider Premium here.

AUSTIN, Texas, Aug. 18, 2022 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Alzheimer’s Disease Prevention Journal (JPAD) that there is no compelling evidence to support claims of data manipulation in a 2020 paper on simufilam co-authored by company staff and collaborating scientists.

JPAD provided the following statement to the Company on Monday, August 15 after market close, which is reproduced in full below:

“We have completed our review of your article “PTI-125 Reduces Biomarkers of Alzheimer’s Disease in Patients” (JPAD 2020;7(4):256-264). We find no convincing evidence of data manipulation or intent to mislead, and therefore take no action regarding the published article..”

“From the start, I have said that the research misconduct allegations are false, and for good reason – I see no evidence to support these allegations,” said Remi Barbier, President and CEO. direction. “I hope that the written statements of neutral and independent scientific experts will help close the chapter of baseless attacks on our science. At some point, it becomes irrational for our detractors to repeat the same tired old mantra of data manipulation over and over again.

In May 2022, Neurobiology of aging investigated and found no evidence of data manipulation in an article on simufilam published in this journal in 2017. The editor of the journal stated: “A reader informed the editors of concerns about the aforementioned report published on Neurobiology of Aging [i.e., “PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer’s disease pathogenesis.” Neurobiol. Aging, 55:99-114]. These questions were forwarded to the authors, who provided a detailed response, including uncropped Western blot images and relevant photomicrographs, as requested by the editor. The material was evaluated by an independent expert with relevant methodological expertise, the manuscript was scanned by AI-based figure checking software (i.e. Proofig) and all available inputs were taken taken into account by the Processing Editor and the Editor-in-Chief. Overall, the editors found no compelling evidence of data manipulation intended to distort the results..” The full journal record is available online:https://www.sciencedirect.com/science/article/pii/S0197458022000562?via%3Dihub

In December 2021, Cassava Sciences announced that Neuroscience investigated and found no evidence of data manipulation in an article published in this journal in 2005. The editor said: “After careful review of these original documents, Neuroscience found no evidence of manipulation of western blot data or other figures in this publication..” The full editorial note of the journal is available online: https://www.sciencedirect.com/science/article/pii/S0306452221005789?via%3Dihub

A related investigation by academic authorities at the City University of New York (CUNY) is ongoing. Pending a public response from CUNY, the two Neurobiology of aging and Journal of Neuroscience previously published an exceptional “expression of concern,” which is a type of non-standard editorial notice used by academic publishers to raise awareness of a possible problem, according to the Council of Science Editors (2012).

About SimufilamSimufilam is a proprietary small molecule (oral) drug from Cassava Sciences that restores the normal form and function of the altered Filamin A (FLNA) protein in the brain. Cassava Sciences owns worldwide rights to develop and commercialize its Alzheimer’s disease research programs and related technologies, without royalty obligations to third parties.

About Cassava Sciences, Inc.Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. Our new science is based on stabilizing – but not suppressing – an essential protein in the brain. For more information, please visit: https://www.cassavasciences.com.

For more information contact: Eric Schoen, Chief Financial Officer, (512) 501-2450, or [email protected].

Caution Regarding Forward-Looking Statements: This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, regarding: our expectations regarding CUNY’s ongoing investigative activities; our views regarding the lack of evidence to support allegations of research misconduct; our expectations regarding the role of written statements by scientific experts; the potential cessation of attacks on the Company; comments from our employees regarding allegations of data manipulation; the treatment of Alzheimer’s disease; and the potential benefits, if any, of our product candidates. These statements can be identified by words such as “may”, “anticipate”, “believe”, “could”, “expect”, “would”, “plan”, “intend”, ” plan”, “possible”, “potential”, and other words and terms of similar meaning. Drug development and commercialization involves a high degree of risk, and only a small number of research and development programs lead to commercialization of a product. Our clinical results from early-stage clinical trials may not be indicative of full results or results from later-stage or larger-scale clinical trials and do not guarantee regulatory approval. You should not place undue reliance on these statements or on any scientific data that we present or publish.

These statements are based largely on our current expectations and projections regarding future events. These statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, but not limited to, risks relating to the ability of conduct or complete clinical studies in a timely manner, demonstrate the specificity, safety, efficacy, or potential health benefits of our product candidates, the severity and duration of health care precautions given the COVID-19 pandemic, any unforeseen impact of the pandemic on our business operations, and including those described in the section titled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, and future reports to be filed with the SEC. The foregoing sets forth many, but not all, factors that could cause actual results to differ from expectations in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking statements and events discussed in this press release are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in forward-looking statements. Accordingly, you should not rely on forward-looking statements as predictions of future events. Except as required by law, we disclaim any intention or responsibility to update or revise any forward-looking statements contained in this press release. For more information regarding these and other risks relating to our business, investors should consult our filings with the SEC, which are available on the SEC’s website at www.sec.gov.